Gfap-based gene therapy for treatment of retinal diseases
AssigneeFlorida Atlantic University
InventorsC. Kathleen DOREY, Janet C. BLANKS, Howard PRENTICE
Life of this patent
Estimating the term…
Abstract
Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an anti-angiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid constructs and vectors.
Claims20
1-26. (canceled)
A method of preventing, reducing or delaying neovascularization, the method comprising the steps of:
- (a) providing a subject having or at risk of developing neovascularization in a tissue;
- and
- (b) transducing at least one GFAP-expressing cell type of said subject with an expression vector comprising a purified nucleic acid construct comprising:
- at least one nucleic acid encoding an anti-angiogenic protein operably linked to a GFAP promoter, wherein expression of said anti-angiogenic protein by said transduced cell prevents, reduces or delays neovascularization in said tissue in said subject.
A method of preventing, reducing or delaying neovascularization in an eye, the method comprising the steps of:
- (a) providing a subject having or at risk of developing a condition involving neovascularization in a compartment of at least one eye;
- and
- (b) transducing at least one GFAP-expressing cell type in said eye of said subject with an expression vector comprising at least one nucleic acid encoding an anti-angiogenic protein operably linked to a GFAP promoter, wherein expression of said anti-angiogenic protein by said transduced cell prevents, reduces or delays neovascularization in said eye of said subject.
Dependencies are inferred from the claim text.